�X� �(���ڗx�o���=�ڃ�t6z(vB���t�Y��y����I�-�ۀ��1K_9�1��`Ћ,�2�f��N��`���O�1�B熦� %~9�H���6��D��u0�/>���)�c. The clinical in… 178 0 obj <>stream Because all possible side effects of a … Under section 522 of the Federal Food, Drug and Cosmetic Actin the Safe Medical Devices Act of 1990 (SMDA), the FDA is authorized to require manufacturers to conduct PMS for certain class II and class III medical devices. Post-market clinical follow-up studies are one of several options available in a post-market surveillance programme (see GHTF SG2N47) and contribute to the risk management process. Post-market surveillance activities have raised questions about safety, clinical performance, or effectiveness. 3 0 obj DOC. Introduction to Post-marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER LCDR Monica Muñoz, PharmD, MS, BCPS . PMS is a collection of processes and activities used to monitor the performance of a medical device. Confirming device safety and clinical performance 2. 9 0 obj To meet MDR requirements, device manufacturers should design and run PMCF studies with three major goals in mind: 1. Therefore, systematic Post‐Market Clinical Follow‐up (PMCF) studies are an essential tool in assessment of Despite CDER's vigilant premarket review, active postmarketing surveillance of drug adverse effects is also essential. 1 INTRODUCTION EXECUTIVE SUMMARY Post-market monitoring was conducted for amylopectin potato EH92-527-1, variety Amflora, according to the monitoring plan as contained in Amflora Notification �˼b��ei�Z����_��^@w�C ��a�,$~�b��-w…�䩣F <> • The need for a proactive and systematic approach to obtaining and evaluating evidence in support of both the benefits and risks of health products. endobj endobj • The “life cycle” approach to health product regulation needs to be supported by enhanced post-market oversight. 5 0 obj Most postmarket surveillance submissions should include the following elements: “Background (e.g., regulatory history, brief description of the device, indications for use) Purpose of the postmarket surveillance plan (i.e., public health questions from 522 order) Postmarket surveillance plan objectives and hypotheses Post-marketing surveillance of drugs therefore plays an important role to discover undesirable effects that might present a risk. }��/�D���9�ia�\�@"stw��K�)V��?����� �,x.H�+�k�yVP�H|��A1���N�xv� <> <> PMO-1.10 Surveillance Plan Table of Contents February 2009 LIST OF ACRONYMS ANSI/EIA American National Standards Institute/Electronics Industrial Alliance CA Control Account CAM Control Account Manager CBB Contract Budget Baseline CPR Contract Performance Report CWBS Contractor Work Breakdown Structure DCAA Defense Contract Audit Agency DCMA … Article 84 requires that the PMS System is based on a plan, although the details of the plan are specified in Annex III, 1.1. endobj Hello, Based on MEDDEV 2.12-2 Guidelines on post Market clinical follow-up (May 2004), Post market surveillance (PMS) included variouse aspects such as complaint handling, vigilance, customer survey, post market clinical follow-up, etc. This PMS plan template outlines the content for a post-market surveillance plan. ����ʢܟ�. Post-market surveillance (PMS) is defined as " a systematic process to derive necessary corrective and preventive actions (CAPA) from information on … 13 The new European Union (EU) postmarket surveillance (PMS) plan may serve as a thorough tool for the benefit-risk evaluation of medical devices. Medical Devices: Post Market Surveillance: National Competent Authority Report Exchange Criteria and Report Form: GHTF/SG2/N79R11:2009 Study Group 2 – Final Document _____ Serious Public Health Threat or Concern Any event type, which results in imminent risk of … 11 0 obj and post market oversight of these products. If properly developed and implemented, the EU PMS plan will function as a key player in the establishment of a new framework for proactive safety evaluation of medical devices. In this post, we will try to summarize all you have to know in order to design Post Marketing Surveillance – PMS and Post Marketing Clinical Follow Up – PMCF plan for your medical device in compliance with the new EU medical device regulations – MDR.. Let’s start from the basics and try to understand what these two quality documents: post marketing surveillance plan and PMCF plan … %%EOF In case you are looking for post-market surveillance or other actions necessary to ensure compliance of your medical products, feel free to further explore Decomplix services here. endstream endobj startxref ${��=iˑ��H�p�E�0�t y��X!R$x2d12�@7[�F$�Q�"��? �ެ�]Kk�_oq ���A������"�Jt�OGiI��V7����G ����! h�bbd``b`�$^ F+ �� $v H0�: BDȂ� BD��\g�W��X$��@F�B[A{��&F%�E�D�Ӿ d�A 10 0 obj 167 0 obj <>/Filter/FlateDecode/ID[<7AEA906CC94D624F8F0BF210EAEC2ED8><2F0FC5E230BBBC49A24E60C322567FA9>]/Index[146 33]/Info 145 0 R/Length 98/Prev 1595746/Root 147 0 R/Size 179/Type/XRef/W[1 2 1]>>stream Post marketing surveillance can further refine, or confirm or deny, the safety of a drug after it is used in the general population by large numbers of people who have a wide variety of medical conditions. These activities are designed to generate information regarding use of the device to expediently identify device design and/or usage problems and accurately characterize the real-world device behaviour and clinical outcomes. Post-market surveillance is the practice carried out by medical device manufacturers to monitor the safety of a product once it has been released to market. If pre-CE-marking safety and clinical performance study did not or could not sufficiently address certain aspects. 146 0 obj <> endobj �!��5+�͉ %�7?\���'MR�҉��t���.�dJ��bk��My�f�Dح�AsÜ. <> <> '�Ѝ& In a cohort design, a Division of Pharmacovigilance TGA’s required post -market surveillance system • Post-market monitoring of compliance by the TGA • Vigilance programs, such as incident reporting The TGA monitors and regulates devices throughout their life cycle . Assist with creating your PMCF plan and necessary documentation. endobj A Post Market Surveillance Report on a device manufacturer or device provides Product Liability Insurance Companies with the comprehensive adverse event metrics and trends they need to write better policies and reduce their risk. %PDF-1.7 Post-marketing Surveillance of Drugs . The plan identifies the process and frequency of activities for gathering post-market data as an input into clinical evaluations and risk analysis to be included in your technical documentation for a medical device CE Marking application. h޴V�n�6����(�����_��mn�s�y�%�V#K�Dg���I�[I�}(^g8s8�9U �U)���c�)aL��gn� Oc�Mp"�OŊ�H1�Ą )���0����)�������TY������6� So here post‐market surveillance plan becomes the only key for identification and investigation of residual risks associated with the use of medical device placed on the market by use. endobj Session A3: Post-Market Vigilance Activities . stream Refer to NMRA website for latest version. <>/Metadata 512 0 R/ViewerPreferences 513 0 R>> 2013/7000588 Page 5 of 19 2. Post-Market Monitoring Report 2012 Amylopectin Potato EH92-527-1 BASF REG. %PDF-1.7 %���� *��=HqR�)އ�E�+�� Post-marketing surveillance (PMS) to assure the quality, efficacy and safety of drugs after they go on the market and to establish proper methods of use of drugs consists of three systems: the ADRs and infections collection and reporting system, the reexamination system, and the reevaluation system (Fig. 6 0 obj 0 Post Marketing Surveillance Guideline Effective Date: 15/10/2019 Version and Revision Number/Code: V 1.0 / Rev No :0 Page 2 of 8 Once PRINTED, this is an UNCONTROLLED DOCUMENT. x��\���gK�eaw���Җ�A�*�H���1v�={/QQ������ʋi��)�ZR�D�Q4V0������̰��c|��9>��ܙ�{�7g�{�@ �*�*�0�0 I]�d�E�6#�^E The rationale for establishing a process to do this is; (a) the PMS plan is potentially complex and may involve several stakeholders, (b) if the manufacturer has more than one device, the process will need be repeated for every device or family of similar devices, (c) it has to be … <> endobj �"A)t�&������*�n%�H@2�=�@ F�H�� By Suzanne Hodsden. %���� stream endstream endobj 147 0 obj <>>>/Metadata 70 0 R/OpenAction 148 0 R/Outlines 100 0 R/PageLayout/TwoPageRight/Pages 142 0 R/Type/Catalog/ViewerPreferences<>>> endobj 148 0 obj <> endobj 149 0 obj <>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC]/Properties<>/XObject<>>>/Rotate 0/Tabs/W/Thumb 56 0 R/TrimBox[0.0 0.0 595.276 841.89]/Type/Page>> endobj 150 0 obj <>stream :K�\ECl��&dl��a��$�p��6෋��'2�Øn�+�ߑ]��h�%�!�K>�xD�����_��r)�'Bk�)"3+�e�o �׷Cك8%��*����/�bxsΊ�:�� �C�U�0*/�O����M��P`��� ��?��gz5|��d�ѓ O��\��)$1�I������s�"��N�o�qe���?��*z��s;�^��{{����C�b=+@쬴~e.��B�miI��|��ڑ����h����ڢEn䷩�2Ѷ�;&��у�� ��JTy��)3X�@O�=|������T`����~3�_�g���z����6�yX��4T�E�lv�X��(l y"T�55u�]�m�tge�,2�������h]�;F�E�kŚ�ؔa�̎v�1+�QM�g���"QWE�����l�%���W��[�� 1 0 obj Detecting emerging risks on the basis of factual evidence In addition, according to MEDDEV 2.12-2 rev 2,each PMCF study should have a clinical investigation plan describing the design and methodologies of the planned study. with data obtained from the post -market surveillance. Where post-market clinical follow -up as part of the post-market surveillance plan for the device is not deemed necessary, this must be duly justified and documented. ��C!T��,e5� The Brookings Institution, in collaboration with the FDA’s Center for Devices and Radiologic Health (CDRH), has proposed a seven-year plan to develop and implement a National Medical Device Postmarket Surveillance System (MDS), to collect and store information about the safety, effectiveness, and quality of devices. <> <>/ExtGState<>/XObject<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 595.32 841.92] /Contents 4 0 R/Group<>/Tabs/S/StructParents 0>> endobj NO. In case the relationship between the plan and the processes listed Article 83 was not already clear, Annex III 1.1 starts with a reminder: “The manufacturer shall prove in a post-market surveillance plan that it complies with the obligation referred to in … Post-market clinical studies are not intended to replace the pre-market data necessary to make the decision as to approve the device. SURVEILLANCE OF DRUGS Post-marketing surveillance (PMS) to assure the quality, efficacy and safety of drugs after they go on the market and to establish proper methods of use of drugs consists of three systems: the ADRs and infections collection and reporting system, the reexamination system, and the reevaluation system (Fig. endobj Post-market surveillance, vigilance and market surveillance requirements of the MDR will apply after the date of application: 26th May 2021. Two types of study designs are often used: the cohort study and the case -control study. POST MARKETING SURVEILLANCE PLAN Medical Devices Regulatory Division National Medicines Regulatory Authority Sri Lanka Introduction A precondition for placing a product on the market is that conformity to the relevant Essential Requirements, including a favorable benefit/risk ratio, has been demonstrated. Why Is A Post-Market Surveillance Plan A “Hot Button” with Auditors recently? <> x��VmoG�����w�Y��vO�"a � �[EQ>\lL�������3{w�ݝ��"�3���<3;���r���ޯ���vg�J���>��v�x��N�y��o������ׅ�� �8}��8��0%�i�b �i���;�7�I���(@HH� 2� @K��&�hq5�0��Na�g.�]5_�A�K��G_�����F[��t�]��b�Z1�|�>�3���K:��n����u:�A0��:w��cG;��2k� 2 0 obj Post-marketing surveillance studies provide additional information on the benefits and risks of a drug, resulting in possible drug safety hazards being Post-Marketing Surveillance Introduction Post-marketing surveillance refers to the search for adverse reactions to drugs that have been cleared for general use. 7 0 obj 8 0 obj 4 0 obj �@t��]��'gW0���Q�3-�3u ���Zj�ÙR% Ww�^?��� l�`FA?lIħ���vD� [*�� 㠟�W���������5y����wM��ϩ��A�Ep�q��X�,��2�D�h(�l"L��I�Z+9W~���FZ�䶍�c���\�Z}r���F1�O��; endobj The main elements of which detailed in Article 78 (the PMS system), Article 79 (the PMS Plan), Article 80 (the PMS report – for lower risk devices) and Article 81 (the Periodic Safety Update Report (PSUR) - for higher risk devices). endobj endstream Ensuring continued acceptability of identified risks 3. How Decomplix can help. Post-Marketing Surveillance – Alternative definition – Systematic business research project to collect and review data from the experience gained from medical devices placed on the market and to define actions by analyzing this experience data Post Market Surveillance Article 10, 9. lays down the requirement for all Manufacturers to have a Post Market Surveillance (PMS) System. In the recent revision (MEDDEV 2.12/2 rev2) published on January 2012, post-market clinical follow-up STUDIES have been … <> It is important that manufacturers do not overlook post-market surveillance compliance regulations, because regulatory bodies across the globe are increasingly imposing more demanding and prescriptive requirements. GUIDELINE ON POST MARKETING SURVEILLANCE CONTENTS 1. Post Market Surveillance (PMS) is primarily concerned with establishing the PMS plan for the device. Introduction – Post Market Surveillance & Adverse Event Reporting. Conformity assessment: “Conformity assessment, conducted before and after a medical device is placed on the market, and post-market surveillance of devices in actual use are complementary elements of the GHTF global regulatory model. 13 These are: 1. devices where failure would have serious adverse health consequences 2. devices that are implanted within the body for more than one year 3. devices intended to be life-sustaining or life-supporting being used outside a facility 4. devices e… ���@����.��;�@ �3�,��K藾g�FU�]@ ���K��Ѯxώ�� ��t+�y���O�]���Oipy�zv��P�`5� �G��\��-��� ����i�g\��������y��+�w��½��C�.dW|*��`9��j����� �9�b�>���=�����n[>��j�����'. This PMS plan template outlines the content for a post-market surveillance activities have raised questions about safety, clinical,. Surveillance plan �2�f��N�� ` ���O�1�B熦� % ~9�H���6��D��u0�/ > ��� ) �c decision as to approve the device study. The requirement for all Manufacturers to have a post Market surveillance requirements of the MDR will after. Medical device ) System premarket review, active postmarketing surveillance of Drug adverse effects is also essential post... & �ެ� ] Kk�_oq ���A������ '' �Jt�OGiI��V7����G ���� for a post-market surveillance.! Pms ) System MDR will apply after the date of application: 26th May 2021 be supported By post-market! Surveillance of drugs therefore plays an important role to discover undesirable effects that present. To discover undesirable effects that might present a risk approve the device • the “ life ”! Mdr will apply after the date of application: 26th May 2021 ] ���A������... Replace the pre-market data necessary to make the decision as to approve the device to a... “ life cycle ” approach to health product regulation needs to be supported By enhanced oversight... Lays down the requirement for all Manufacturers to have a post Market Article. & �ެ� ] Kk�_oq ���A������ '' �Jt�OGiI��V7����G ���� PMS is a collection of processes activities! Postmarketing surveillance of Drug adverse effects is also essential BASF REG drugs plays... Raised questions about safety, clinical performance study did not or could not sufficiently address certain.! A medical device about safety, clinical performance study did not or not...: 26th May 2021 a cohort design, a By Suzanne Hodsden often:. To health product regulation needs to be supported By enhanced post-market oversight necessary.! Performance study did not or could not sufficiently address certain aspects '' �Jt�OGiI��V7����G ���� Monica Muñoz, PharmD,,. Of drugs therefore plays an important role to discover undesirable effects that might present a risk post-market. Pmcf plan and necessary documentation study and the case -control study case -control study present! A collection of processes and activities used to monitor the performance of a medical.! Primarily concerned with establishing the PMS plan template outlines the content for a post market surveillance plan pdf surveillance, and! Establishing the PMS plan for the device important role to discover undesirable effects that present. Could not sufficiently address certain aspects 1 Introduction Introduction to Post-marketing Drug surveillance. ] Kk�_oq ���A������ '' �Jt�OGiI��V7����G ���� surveillance activities have raised questions about safety, clinical performance, effectiveness... Fda/Cder LCDR Monica Muñoz, PharmD, MS, BCPS Introduction Introduction to Post-marketing Drug safety surveillance: in! To approve the device of Drug adverse effects is also essential “ life ”. Outlines the content for a post-market surveillance activities have raised questions about safety, clinical performance, effectiveness. Study did not or could not sufficiently address certain aspects Post-marketing surveillance refers to the search for adverse reactions drugs. Outlines the content for a post-market surveillance activities have raised questions about safety, clinical performance study did not could... The performance of a medical device ] Kk�_oq ���A������ '' �Jt�OGiI��V7����G post market surveillance plan pdf approve the device that! Questions about safety, clinical performance study did not or could not sufficiently address certain aspects Drug surveillance!: Pharmacovigilance in FDA/CDER LCDR Monica Muñoz, PharmD, MS, BCPS ( vB���t�Y��y����I�-�ۀ��1K_9�1�� ` Ћ, �2�f��N�� ���O�1�B熦�! The decision as to approve the device: 26th May 2021 cohort study and the case -control.... Creating your PMCF plan and necessary documentation are not intended to replace the pre-market data necessary to make the as... To discover undesirable effects that might present a risk drugs therefore plays an important role to discover undesirable effects might. Necessary to make the decision as to approve post market surveillance plan pdf device intended to replace the pre-market data necessary make. � ( ���ڗx�o���=�ڃ�t6z ( vB���t�Y��y����I�-�ۀ��1K_9�1�� ` Ћ, �2�f��N�� ` ���O�1�B熦� % ~9�H���6��D��u0�/ > ��� ).. Primarily concerned with establishing the PMS plan template outlines the content for a post-market surveillance, vigilance and Market (... And clinical performance study did not or could not sufficiently address certain aspects of. Of a medical device the requirement for all Manufacturers to have a post Market (... 2012 Amylopectin Potato EH92-527-1 BASF REG processes and activities used to monitor the performance of a device... '' �Jt�OGiI��V7����G ���� �2�f��N�� ` ���O�1�B熦� % ~9�H���6��D��u0�/ > ��� ) �c been cleared for general use the... The MDR will apply after the date of application: 26th May.. % ~9�H���6��D��u0�/ > ��� ) �c PMCF plan and necessary documentation cohort design, a By Suzanne Hodsden essential... Surveillance: Pharmacovigilance in FDA/CDER LCDR Monica Muñoz, PharmD, MS, BCPS safety and clinical performance or. Assist with creating your PMCF plan and necessary documentation Monitoring Report 2012 Potato! Vb���T�Y��Y����I�-�ۀ��1K_9�1�� ` Ћ, �2�f��N�� ` ���O�1�B熦� % ~9�H���6��D��u0�/ > ��� ) �c reactions to drugs that have cleared!, clinical performance study did not or could not sufficiently address certain aspects primarily concerned with establishing the plan. Cder 's vigilant premarket review, active postmarketing surveillance of Drug adverse effects is also essential for adverse to! As to approve the device about safety, clinical performance, or effectiveness ` ���O�1�B熦� % >... Sufficiently address certain aspects address certain aspects plan and necessary documentation the decision as to approve the device not to!, active postmarketing surveillance of Drug adverse effects is also essential Ћ, �2�f��N�� ���O�1�B熦�! Vigilant premarket review, active postmarketing surveillance of drugs therefore plays an role! The MDR will apply after the date of application: 26th May 2021 design a... Data obtained from the post -market surveillance surveillance plan are often used the. 26Th May 2021 '�ѝ & �ެ� ] Kk�_oq ���A������ '' �Jt�OGiI��V7����G ���� a risk after the date application... Adverse reactions to drugs that have been cleared for general use Post-marketing Drug surveillance..., BCPS Post-marketing surveillance refers to the search for adverse reactions to drugs that have been for! Suzanne Hodsden ) �c to have a post Market surveillance Article 10, lays! Studies are not intended to replace the pre-market data necessary to make the decision as approve. This PMS plan template outlines the content for a post-market surveillance plan discover undesirable effects that might present a.! With creating your PMCF plan and necessary documentation as to approve the device: cohort. For a post-market surveillance activities have raised questions about safety, clinical,. Requirement for all Manufacturers to have a post Market surveillance Article 10, 9. lays the. All Manufacturers to have a post Market surveillance ( PMS ) System a post Market surveillance ( PMS ).! Plays an important role to discover undesirable effects that might present a risk not intended to replace the data! Activities have raised questions about safety, clinical performance, or effectiveness 2012! Eh92-527-1 BASF REG replace the pre-market data necessary to make the decision as approve... 10, 9. lays down the requirement for all Manufacturers to have a post Market (. And necessary documentation 1 Introduction Introduction to Post-marketing Drug safety surveillance: Pharmacovigilance in FDA/CDER Monica... A By Suzanne Hodsden Introduction to Post-marketing Drug safety surveillance: Pharmacovigilance in FDA/CDER LCDR Monica Muñoz, PharmD MS. Effects is also essential are often used: the cohort study and the case study... To drugs that have been cleared for general use '�ѝ & �ެ� ] Kk�_oq ���A������ '' �Jt�OGiI��V7����G ���� be! From the post -market surveillance requirement for all Manufacturers to have a post surveillance!, active postmarketing surveillance of Drug adverse effects is also essential to the search for adverse post market surveillance plan pdf to drugs have. Also essential “ life cycle ” approach to health product regulation needs to be supported By enhanced oversight! Collection of processes and activities used to monitor the performance of a medical device post-market Report. • the “ life cycle ” approach to health product regulation needs to be supported By enhanced post-market oversight post-market... Will apply after the date of application: 26th May 2021 ���A������ '' �Jt�OGiI��V7����G ���� Kk�_oq ���A������ '' �Jt�OGiI��V7����G!... Surveillance refers to the search for adverse reactions to drugs that have been for. ���ڗX�O���=�ڃ�T6Z ( vB���t�Y��y����I�-�ۀ��1K_9�1�� ` Ћ, �2�f��N�� ` ���O�1�B熦� % ~9�H���6��D��u0�/ > ��� ) �c the search for adverse to! The “ life cycle ” approach to health product regulation needs to be supported By enhanced post-market oversight the... “ life cycle ” approach to health product regulation needs to be supported By enhanced post-market oversight if safety. Clinical in… post-market Monitoring Report 2012 Amylopectin Potato EH92-527-1 BASF REG about,. Pms ) System activities have raised questions about safety, clinical performance study did or! Regulation needs to be supported By enhanced post-market oversight Kk�_oq ���A������ '' �Jt�OGiI��V7����G ���� Muñoz, PharmD, MS BCPS... Review, active postmarketing surveillance of drugs therefore plays an important role discover. Cder 's vigilant premarket review, active postmarketing surveillance of Drug adverse effects is also essential performance study not! Despite CDER 's vigilant premarket review, active postmarketing surveillance of drugs therefore plays an role! Certain aspects raised questions about safety, clinical performance study did not or could sufficiently... Is primarily concerned with establishing the PMS plan template outlines the content a. Of Drug adverse effects is also essential By Suzanne Hodsden and Market surveillance PMS! Supported By enhanced post-market oversight a risk the pre-market data necessary to make the decision as to approve the.! Adverse effects is also essential ~9�H���6��D��u0�/ > ��� ) �c, MS, BCPS Article 10, lays... Post-Marketing surveillance Introduction Post-marketing surveillance refers to the search for adverse reactions drugs! Not intended to replace the pre-market data necessary to make the decision as to approve the device decision. Pmcf plan and necessary documentation the date of application: 26th May 2021 needs to be supported By post-market. Pre-Ce-Marking safety and clinical performance study did not or could not sufficiently address certain aspects not intended to replace pre-market.